Gilead Sciences on Monday announced new study data suggesting that its Quad pill reduced HIV virus counts to undetectable levels in 90 percent of patients after 48 weeks, compared with 83 percent of patients given the company's Atripla. Calling the data "very strong, very robust," Steve Chuck, vice president of HIV therapies at Gilead said "the 48-week data confirmed and extended the results that we saw at 24 weeks."
Reference Articles
Gilead quad HIV pill tops best-selling Atripla in 48-week study - (Bloomberg)
Gilead says Quad pill suppresses HIV at 48 weeks - (FinanzNachrichten)
Gilead's single-tablet "Quad" HIV regimen maintains high viral suppression through 48 weeks in Phase II study - (Gilead Sciences)
**Published by "First Word"
No comments:
Post a Comment